Headache and Migraine

 
FDA Approves Intranasal DHE (Trudhesa) for Acute Migraine Treatment
September 14, 2021

The DHE nasal spray delivered pain relief at 2 hours for 66% of patients; 93% of those remained pain-free at 24 hours and 86% at 2 days post-dose.

Atogepant for Migraine Prevention Meets Primary, Secondary Endpoints
August 23, 2021

Oral CGRP inhibitor atogepant significantly reduced monthly headache days and improved daily function in adults with 4 to 14 headaches per month.

Neurology, Rheumatology, and the Gut Microbiome: Two Specialists Discuss
July 16, 2021

A neurologist and a rheumatologist sat down with Patient Care editors to talk about their focus on balance in the gut microbiome as an essential element of clinical care.